Japan’s Laws Supporting Accelerated Pathways for Cell Therapies
In late 2014, Japan passed two new laws that revolutionized the commercialization of cell therapies within the country by providing an accelerated pathway for product approvals. While there has been much discussion about these laws, few people have a clear understanding of the implications of these regulations on a global scale.
Below, we summarize the laws, identify their importance, and most importantly, speak to how Japan has become a “gateway country” for regenerative medicines. [Read more…]
Cellular Dynamics International Sends iPSCs to International Space Station on NASA Resupply Mission
MADISON, Wis., Dec. 27, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity. [Read more…]
ORIG3N, World’s Largest Blood Cell Repository for iPS Cell Production
ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
Gladstone Institutes Initiates Research Collaboration With Eli Lilly for Neurodegenerative Diseases
Study will use innovative technology to focus on neurodegenerative diseases
SAN FRANCISCO, December 7, 2017 (Newswire.com) – The Gladstone Institutes announced today a new research collaboration with Eli Lilly and Company focused on neurodegenerative diseases. This multi-year, milestone-driven project will be based on a combination of innovative technologies developed at Gladstone by Steve Finkbeiner, M.D., Ph.D. His laboratory will work closely with Lilly during this collaboration.
“This collaboration has high potential to open new avenues towards effective therapies for neurodegenerative diseases,” said Gladstone President R. Sanders Williams, M.D. “Both organizations are committed to meeting this major unmet need.”
Key to the project is a robotic microscope system developed in Finkbeiner’s laboratory with funds from Gladstone, the Taube/Koret Center for Neurodegenerative Disease Research, and the ALS Association. This fully automated platform allows scientists to track thousands of individual cells for days or weeks at a time, and follow discrete cellular functions.
When coupled with neurons generated from induced pluripotent stem cells collected from patients with neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS, this microscope becomes a powerful tool to study the cells and their responses to disease and treatments. [Read more…]
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 201
- Next Page »